Whole-blood transfusion has recently gained favor in the management of severe hemorrhage; however, data from large clinical trials evaluating its clinical effectiveness and safety are lacking. We ...
Oral semaglutide (a GLP-1 pill) is not effective at slowing progression in patients with mild Alzheimer's disease, finds the ...
Metronidazole-Based Standard of Care with Favorable Tolerability MIAMI BEACH, Fla., March 19, 2026 /PRNewswire/ -- Crescel LLC, an innovative science and technology company, today announced results ...
Providence Medical Technology, Inc., a pioneer in less invasive solutions for spine surgery, today announced enrollment of ...
GlobalData on MSN
Mirum concludes Phase III EXPAND trial enrolment for Livmarli
The double-blind, randomised, placebo-controlled trial will assess the efficacy and safety of Livmarli in both children and ...
Two large phase 3 trials found that oral semaglutide 14 mg did not slow cognitive or functional decline over 104 weeks in ...
Oxaliplatin-Based Versus Alkylating Agent in Neuroendocrine Tumors According to the O6-Methylguanine-DNA Methyltransferase Status: A Randomized Phase II Study (MGMT-NET) The median time post-HCT was ...
Hand-foot syndrome (HFS) is a dose-limiting side effect of capecitabine. Celecoxib prevents HFS by inhibiting cyclooxygenase-2 (COX-2) that is upregulated because of the underlying associated ...
Medical Device Network on MSN
Providence Medical enrols first patients in CORUS-LX system trial
Subjects are randomised to receive posterior fusion using either the CORUS-LX system or the standard posterior fusion method.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results